The pharmaceutical giant said its profit was impacted by a large charge related to its recent merger with Schering-Plough, but still managed to top analyst estimates. Looking forward, Merck lifted the lower end of its 2010 earn…
Tiny, little-known biotech Clinical Data has developed a potential blockbuster drug called Vilazodone. If OK’d, it would be the first new depression treatment in 15 years. Its potential is so huge that several Big Pharmas are s…
Dozens of companies report earnings this week, and analysts surveyed by Thomson Reuters are anticipating lots of strong quarterly reports. Among those posting improved results should be Microsoft and Visa. However, likely to p…
Regardless of where the index stands, since the Dow gets so much attention, it’s interesting to note how its components are pushing and pulling on the measure. Let’s look at how the various component stocks are performing.
…
Federal investigators are looking into allegations that major drug companies, including Merck, AstraZeneca, Bristol-Myers Squibb and GlaxoSmithKline, paid bribes overseas to boost sales and accelerate approvals.
…